Skip to main content

Table 1 Baseline demographics and disease severity by ADT group (safety sample)

From: Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study

Baseline characteristic

Bupropion plus aripiprazole (n = 46)

SSRI/SNRI plus aripiprazole (n = 242)

Age (years), mean (SD)

45.0 (12.9)

46.6 (12.6)

Gender, n (%)

  

  Females

30 (65.2)

166 (68.6)

Race, n (%)

  

  White

40 (87.0)

223 (92.1)

  Black

4 (8.7)

12 (5.0)

  Asian

0

2 (0.8)

  Other

2 (4.3)

5 (2.1)

Weight (kg), mean (SD)

93.4 (23.2)

87.7 (22.4)

BMI (kg/m2), mean (SD)

32.5 (8.6)

31.2 (8.1)

CGI-S score, mean (SD)

4.2 (0.6)

4.2 (0.6)

MADRS Total score, mean (SD)

24.5 (4.8)

25.1 (6.0)

IDS-Self Rated Total score, mean (SD)

34.6 (9.4)

38.2 (10.5)

QIDS-Self Rated Total score, mean (SD)

13.5 (3.9)

14.6 (4.2)

  1. CGI-S, Clinical Global Impressions–Severity score; IDS, Inventory of Depressive Symptomatology; MADRS, Montgomery–Åsberg Depression Rating Scale; QIDS, Quick Inventory of Depressive Symptomatology; SD, standard deviation; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.